The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Open accessAbstract
In schizophrenia patients, glutathione dysregulation at the gene, protein and functional levels, leads to N-methyl-D-aspartate (NMDA) receptor hypofunction. These patients also exhibit deficits in auditory sensory processing that manifests as impaired mismatch negativity (MMN), which is an auditory evoked potential (AEP) component related to NMDA receptor function. N-acetyl-cysteine (NAC), a glutathione precursor, was administered to patients to determine whether increased levels of brain glutathione would improve MMN and by extension NMDA function. A randomized, double-blind, cross-over protocol was conducted, entailing the administration of NAC (2 g/day) for 60 days and then placebo for another 60 days (or vice versa). 128-channel AEPs were recorded during a frequency oddball discrimination task at protocol onset, at the point of cross-over, and at the end of the study. At the onset of the protocol, the MMN of patients was significantly impaired compared to sex- and age- matched healthy controls (p=0.003), without any evidence of concomitant P300 component deficits. Treatment with NAC significantly improved MMN generation compared with placebo (p=0.025) without any measurable effects on the P300 component. MMN improvement was observed in the absence of robust changes in assessments of clinical severity, though the latter was observed in a larger and more prolonged clinical study. This pattern suggests that MMN enhancement may precede changes to indices of clinical severity, highlighting the possible utility AEPs as a biomarker of treatment efficacy. The improvement of this functional marker may indicate an important pathway towards new therapeutic strategies that target glutathione dysregulation in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, NAC normalized neuronal activity and connectivity and improved mismatch-negativity (Lavoie et al., 2008), an auditory-related, NMDA-dependent evoked potential typically impaired in schizophrenia (Umbricht et al., 2000).”
From Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? (2016) · cites this paper as Lavoie et al., 2008
In the citing paper
“Published studies have revealed beneficial effects in schizophrenia patients as an add-on to maintenance medication [100][101][102][103] and ongoing studies are following up their results and including additional metrics of efficacy such as brain GSH imaging in order to reflect the BBB permeability analyses of NAC that have been performed in rodents 104 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [102]
In the citing paper
“Other compounds that may reverse MMN deficits in schizophrenia include N-acetylcysteine, a precursor of the brain antioxidant glutathione (59) and D-serine, an endogenous NMDAR modulator (60).”
From Sensory Processing Dysfunction in the Personal Experience and Neuronal Machinery of Schizophrenia (2015) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meister, A., & Anderson, M. E. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.003431 · Cited by 5,694
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Early selective-attention effect on evoked potential reinterpreted
Näätänen, R., Gaillard, A. W. K., & Mäntysalo, S. (1978) · Acta Psychologica · doi:10.1016/0001-6918(78)90006-9 · Cited by 2,725
Diagnostic Interview for Genetic Studies
Nürnberger, J. I. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950110009002 · Cited by 2,075
Michel, C., Murray, M. M., Lantz, G., Gonzalez, S., Spinelli, L., & de Peralta, R. G. (2004) · Clinical Neurophysiology · doi:10.1016/j.clinph.2004.06.001 · Cited by 1,771
Self-citationDecreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
Reference-free identification of components of checkerboard-evoked multichannel potential fields
Lehmann, D., & Skrandies, W. (1980) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(80)90419-8 · Cited by 1,595
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia
Garey, L. J., Ong, W., Patel, T. S., Kanani, M., Davis, A., Mortimer, A. M., Barnes, T., & Hirsch, S. R. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.4.446 · Cited by 719
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–370 of 370
Niosomes loading N-acetyl-L-cysteine for cancer treatment in vivo study
Mohamad, E. A., Ali, A. A., Sharaky, M. M., & El-Gebaly, R. H. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02893-9 · Cited by 4
Wasserthal, S., Muthesius, A., Hurlemann, R., Ruhrmann, S., Schmidt, S. J., Hellmich, M., Schultze‐Lutter, F., Klosterkötter, J., Müller, H., Meyer‐Lindenberg, A., et al. (2024) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgae005 · Cited by 4
Veerapandian, R., Ramos, E., Vijayaraghavan, M., Sedano, M. J., Carmona, A., Chacon, J. A., Gadad, S. S., & Dhandayuthapani, S. (2023) · Biochimie · doi:10.1016/j.biochi.2023.02.010 · Cited by 4
Glutathione Deficit and Redox Dysregulation in Animal Models of Schizophrenia
Steullet, P., Cabungcal, J.-H., Kulak, A., Cuénod, M., Schenk, F., & Kim, Q. (2011) · Neuromethods · doi:10.1007/978-1-61779-157-4_7 · Cited by 4
Self-citationKulak, A. (2012) · Schizophrenia Research · doi:10.1016/s0920-9964(12)70162-7 · Cited by 4
Yu, Q., Guo, K., Yang, Y., Liu, H., Han, Y., Yu, X., Wang, J., Zhao, Y., Su, X., Zhu, K., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04251-2 · Cited by 3
Choi, G., Kim, S., Noeske, R., Moore, J. E., Lee, G. H., Kim, J., Newton, A. T., Robison, R. K., Chang, Y., & Choi, C. (2025) · NMR in Biomedicine · doi:10.1002/nbm.5313 · Cited by 3
The Emerging Role of N-Acetylcysteine in Psychiatry: A Narrative Review of Available Data
Marazziti, D., Caruso, V., Cappellato, G., Chiarantini, I., Gurrieri, R., Perrone, P., Violi, M., Crivelli, N. S. B., Weiss, F., & Perugi, G. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673365458250901115725 · Cited by 3
Jose, R., Venketeswaramurthy, N., & Sambath Kumar, R. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i8.23259 · Cited by 3
Näätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.003.0003 · Cited by 5
Shea, T. B. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.07.039 · Cited by 3
Structure models of G72, the product of a susceptibility gene to schizophrenia
Kato, Y., & Fukui, K. (2016) · The Journal of Biochemistry · doi:10.1093/jb/mvw064 · Cited by 3
Perrotta, C., Carnovale, C., Pozzi, M., Palma, C. D., Cervia, D., Nobile, M., & Clementi, E. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100061 · Cited by 3
Szkudlarek, H. J., Mann, R. S., Wieczerzak, K. B., Sarikahya, M. H., Uzuneser, T. C., Felice, M. D., Rodríguez-Ruiz, M., Galindo, J. P., Pusparajah, M., Whitehead, S. N., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03580-4 · Cited by 2
Role of mitochondria in brain functions and related disorders
Yadav, M., Dahiya, M., Dagar, J., Singh, N., Sharma, N., Rawat, N., Dhakla, P., Minocha, N., & Kumar, A. (2022) · Exploration of Medicine · doi:10.37349/emed.2022.00110 · Cited by 2
The protective effect of N-acetylcysteine against MK-801-induced neurodegeneration in mice
AKOSMAN, M. S., Türkmen, R., & Demirel, H. H. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08881-9 · Cited by 3
Brain imaging correlates of emerging schizophrenia
Ehlkes, T., Michie, P. T., & Schall, U. (2012) · Neuropsychiatry · doi:10.2217/npy.12.13 · Cited by 2
Rapp, P. E., Cellucci, C. J., Darmon, D. M., & Keyser, D. O. (2022) · Psychiatry International · doi:10.3390/psychiatryint3020015 · Cited by 1
Use of N-acetylcysteine in Obsessive-Compulsive and Related Disorders
Memik, N. Ç., Gündoğdu, Ö. Y., & Tural, Ü. (2015) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20140811064455 · Cited by 2
Naturalne metody wspomagania odporności w walce z koronawirusem
Jankowska, K. K., & Suszczewicz, N. (2020) · Wiedza Medyczna · doi:10.36553/wm.52 · Cited by 2
Cognitive impairments in schizophrenia and their impact on oxidative stress
Piatoikina, A. S., Zhilyaeva, T. V., & Mazo, G. E. (2022) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2022-56-3-66-79 · Cited by 1
Biswas, A., Singh, G., Arya, V., Lakhotia, S. C., & Sinha, D. (2026) · Journal of Cell Science · doi:10.1242/jcs.264402 · Cited by 1
Oxidative stress, antioxidant defenses, and schizophrenia
Ong, W., Sim, K., & Farooqui, A. A. (2010) · Asia-Pacific Psychiatry · doi:10.1111/j.1758-5872.2010.00090.x · Cited by 1
Conus, P., & Do, K. Q. (2010) · L information psychiatrique · doi:10.1684/ipe.2010.0647 · Cited by 1
Self-citationNeurophysiology of Cognitive Dysfunction in Schizophrenia
Haenschel, C., & Linden, D. E. J. (2011) · Springer eBooks · doi:10.1007/978-94-007-0831-0_18 · Cited by 1
Nonpharmalogical Substances for Early Intervention
Conus, P. (2016) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000440922 · Cited by 1
Self-citationNeuroinflamation Treatment Options in Resistant Schizophrenia—State of the Art
de Sá, Z. C., Buinho, A., de Oliveira, T. M., Soares, F. R., Rema, J., & Novais, F. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00356-x · Cited by 1
Development of novel therapy of schizophrenia in children and adolescents
Klein, C., & Bespalov, A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.933806 · Cited by 1
Will the Treatment Protocols for Schizophrenia be Changing Soon?
Littrell, J. L. (2014) · Social Work in Mental Health · doi:10.1080/15332985.2014.894487 · Cited by 1
A Spectroscopic Study of Interaction of Auricyanide with n-Acetylcysteine
Kazimi, S. G. T., Iqbal, M. S., & Shaw, C. F. (2017) · Biological Trace Element Research · doi:10.1007/s12011-017-1149-1 · Cited by 1
Applications of Neurophysiological Biomarkers in CNS Drug Development: Focus on Psychoses
Joshi, Y. B., Tarasenko, M. A., & Light, G. A. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00012-6 · Cited by 1
Lutgen, V. (2012) · e-Publications@Marquette (Marquette University) · Cited by 1
Conus, P., & Kim, Q. (2010) · L information psychiatrique · doi:10.3917/inpsy.8606.0484
Self-citationEstrés Oxidativo y Esquizofrenia
Prados, A. B. (2014) · Gredos (University of Salamanca) · doi:10.14201/gredos.124073
Korostenskaja, M. (2008) · Työväentutkimus Vuosikirja
À la Rencontre de Pierre Magistretti
Parizot, S., & Conus, P. (2010) · L information psychiatrique · doi:10.1684/ipe.2010.0652
Self-citationImproving the quality of life in tuberculosis patients with N - acetylcysteine
Farazi, A., Sofian, M., & Jabbariasl, M. (2014)
Blood-based Biomarkers for Personalised Medicine Applications in Schizophrenia
Tomasik, J. (2014) · EUR Research Repository (Erasmus University Rotterdam)
Balu, D. T., & GOFF, D. C. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.005
Investigating neurobiological mechanisms linking depression and inflammation
Hasebe, K. (2017) · Figshare
Alternative Treatments for Obsessive-Compulsive Disorder: Nutraceuticals and Lifestyle Interventions
Sarris, J. J., & Oliver, G. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108164313.023
Näätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.003.0002
Electroencephalography and Staging
Lavoie, S. (2019) · Cambridge University Press eBooks · doi:10.1017/9781139839518.010
Self-citationAKOSMAN, M. S., Türkmen, R., & Demirel, H. H. (2021) · Research Square · doi:10.21203/rs.3.rs-471055/v1
Amini, A., Masoumi-Moghaddam, S., & Morris, D. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-28570-2_4
Näätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.003.0008
Näätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.003.0005
Näätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.003.0004
À la Rencontre de Pierre Magistretti
Parizot, S., & Conus, P. (2010) · L information psychiatrique · doi:10.3917/inpsy.8606.0529
Self-citationNäätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.003.0007
Näätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.003.0006
The Protective Effect of N-Acetylcysteine on MK-801 Induced Neurodegeneration in MicePreprint
AKOSMAN, M. S., Türkmen, R., & Demirel, H. H. (2022) · Research Square · doi:10.21203/rs.3.rs-1553614/v1
Özcan, Ö. Ö., Karahan, M., & Konuk, M. (2023) · Food bioactive ingredients · doi:10.1007/978-3-031-41188-5_10
Näätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.002.0007
Näätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.002.0003
Näätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.002.0010
Näätänen, R., Kujala, T., & Light, G. A. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198705079.002.0005
Sammi, S. R., Boonpraman, N., Kuhn, N. C., & Cannon, J. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.01.657248
Kow, C. S., Ramachandram, D. S., Hasan, S. S., & Thiruchelvam, K. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01876-x
Schizophrenia and amino acids in diet – it is possible to enhance treatment through nutrition?
Sadko, K. G., Wichowicz, H., Jabłońska, P., & Wolszczak, A. (2025) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2025.0020
Neurophysiology of mismatch negativity generation: a biophysical modeling studyPreprint
Pujol, C. F., Bruce, J., Thorpe, R. V., Jones, S. R., & Dykstra, A. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.08.687373 · Cited by 1
Dysregulation of System Xc- and Its Impact on Cocaine Seeking
Madayag, A. (2012) · e-Publications@Marquette (Marquette University)
Rogóż, Z., & Wąsik, A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00853-7
Ragalmuto, F., Oranje, B., & Ziermans, T. B. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106764
N-Acetylcysteine in Schizophrenia: A Convergent Redox-Based Approach to Therapeutic Potential
Rubio-Contreras, E., Pérez‐Toribio, A., Alvaro, P., Cosialls, A. M., & Morén, C. (2026) · Antioxidants · doi:10.3390/antiox15101277
Metadata
- Authors
- Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., Fornari, E., Meuli, R., Solida, A., Vianin, P., Cuénod, M., Buclin, T., & Do, K. Q.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- Mental Health Research Institute (AU)
- Monash University (AU)
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2007-11-14
- Volume
- 33
- Issue
- 9
- Pages
- 2187-2199
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2003906510
- Cited by
- 371
- References
- 67
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 4 · 2023: 15 · 2022: 10 · 2021: 22 · 2020: 21 · 2019: 33 · 2018: 16 · 2017: 27 · 2016: 19 · 2015: 28 · 2014: 31 · 2013: 23 · 2012: 28
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Own your potential (DEAKIN) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Stanley Medical Research Institute
- Centre d'Imagerie BioMédicale
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- N-acetylcysteine, glutathione, schizophrenia, mismatch negativity, NMDA receptor hypofunction, auditory evoked potentials, P300, auditory sensory processing, glutathione precursor
- MeSH terms
- Acetylcysteine, Acoustic Stimulation, Adult, Brain Mapping, Cerebral Cortex, Contingent Negative Variation, Discrimination, Psychological, Double-Blind Method, Electroencephalography, Evoked Potentials, Auditory, Female, Glutathione, Humans, Male, Middle Aged, Neuropsychological Tests, Reaction Time, Retrospective Studies, Schizophrenia, Time Factors, Free Radical Scavengers, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
